• Tue news: Novo looks to speed up India Wegovy launch. 4 revelations from MN’s 340B transparency report. 4 oral GLP-1R’s in dev. Roche autoimmune partnership. Gilead-Tubulis alliance. See more on our front page

GET OUT

anonymous

Guest
Why are reps still staying here? Bringing in a outside person for a RSM role instead of promoting internally should be the last straw. There is zero chance of upward mobility and zero diversity. Its a miracle this place hasn't been sued yet.
 












Why are reps still staying here? Bringing in a outside person for a RSM role instead of promoting internally should be the last straw. There is zero chance of upward mobility and zero diversity. Its a miracle this place hasn't been sued yet.


I think an inside person was supposed to get the job…..
 


















Why are reps still staying here? Bringing in a outside person for a RSM role instead of promoting internally should be the last straw. There is zero chance of upward mobility and zero diversity. Its a miracle this place hasn't been sued yet.
Another promotional job where inside people were passed over for an outsider. There are zero promotable jobs at this company. Stock is pathetic, and no LTI.
 
























They do need to increase base pay more inline with other specialty roles or more reps will leave, regardless of how good they have it.
Except this job isn't a specialty role. Selling in a pod (yes, we are in a pod with Abbvie), and calling on PCP's, is a far cry from a specialty role. Maybe TM can buy us all an alumni award and promote it on LinkedIn to make up for driving this thing into the abyss.
 






They do need to increase base pay more inline with other specialty roles or more reps will leave, regardless of how good they have it.
Specialty role!! Lmfao!! It’s a retail med sold to PCPs and some GIs. No specialty pharmacy, no hub needed to navigate payer approvals, small molecule old school drug. The only thing special about it is the IQ of someone thinking it’s “specialty”
 






No one wants to comment on the HORRIBLE data readout yesterday and the loss of over $1 BILLION in market cap?

Tom McCourt is an absolute CLOWN! Spending $1B for an asset that sucks and tanking the stock some more. What a joke of a company this is.